A study using patient-derived MET-amplified gastric cancer xenografts demonstrated that these tumors did not respond to a selective MET inhibitor but responded to combined treatment with MET and FGFR2 inhibitors, which, on additional analysis, highlighted the contribution of FGFR2 overexpression to treatment resistance [64]. This evidence concerns the gene MET and gastric cancer.